JGC
EGRX

J. Goldman & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

J. Goldman & Co’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-87,500
Closed -$458K – 551
2023
Q4 		$458K Buy
+87,500
New +$864K 0.02% 268
2016
Q2 		– Sell
-55,000
Closed -$2.23M – 422
2016
Q1 		$2.23M Buy
+55,000
New +$3.49M 0.14% 176

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

J. Goldman & Co's EGRX Position: Q4 2024 in Review

J. Goldman & Co sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 150,611 shares — an estimated $562K sold.

J. Goldman & Co first reported a position in EGRX in Q1 2016 and held it in 7 quarters. The position peaked at $3.85M in Q4 2021. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • J. Goldman & Co reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • J. Goldman & Co sold 150,611 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $562K.
  • J. Goldman & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 7 quarters.
  • J. Goldman & Co's Eagle Pharmaceuticals, Inc. position peaked at $3.85M in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on J. Goldman & Co's 13F filing for Q4 2024, filed 14 Feb 2025.